XENE-DEF14A-2017

Company

Xenon Pharmaceuticals Inc.

Filed

April 27, 2017

Period of Report

June 1, 2017

Accession Number

0001564590-17-007533

A DEF 14A is a proxy statement sent to shareholders before an annual meeting. It covers executive compensation, board elections, and shareholder votes. Learn more about DEF 14A filings →